TPTE

Summary

TPTE (transmembrane phosphatase with tensin homology, HGNC:12023) is a protein-coding gene on chromosome 21p11.2, encoding Putative tyrosine-protein phosphatase TPTE (P56180). Could be involved in signal transduction. It is a selective cancer dependency (DepMap: 11.1% of cell lines).

This gene encodes a PTEN-related tyrosine phosphatase which may play a role in the signal transduction pathways of the endocrine or spermatogenic function of the testis. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 7179 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 45 total
• Cancer dependency (DepMap): dependent in 11.1% of screened cell lines
• MANE Select transcript: NM_199261

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12023
Approved symbol	TPTE
Name	transmembrane phosphatase with tensin homology
Location	21p11.2
Locus type	gene with protein product
Status	Approved
Aliases	PTEN2, CT44, TPTE1
Ensembl gene	ENSG00000274391
Ensembl biotype	protein_coding
OMIM	604336
Entrez	7179

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000427445, ENST00000612746, ENST00000612957, ENST00000618007, ENST00000622113

RefSeq mRNA: 5 — MANE Select: NM_199261 NM_001290224, NM_001425016, NM_199259, NM_199260, NM_199261

CCDS: CCDS74771, CCDS74772, CCDS74773, CCDS77617

Canonical transcript exons

ENST00000618007 — 24 exons

Exon	Start	End
ENSE00001610754	10569437	10569536
ENSE00001657155	10569683	10569746
ENSE00001659869	10578337	10578418
ENSE00001703755	10559494	10559544
ENSE00001774660	10590462	10590523
ENSE00002206977	10524580	10524688
ENSE00002208831	10567670	10567789
ENSE00002221583	10592293	10592373
ENSE00002229894	10570485	10570549
ENSE00002234792	10561030	10561191
ENSE00002240871	10578517	10578605
ENSE00002295075	10541112	10541165
ENSE00002303771	10602058	10602150
ENSE00002311810	10595982	10596087
ENSE00003725568	10605417	10605716
ENSE00003735534	10538681	10538734
ENSE00003737287	10527355	10527412
ENSE00003738903	10577460	10577520
ENSE00003741695	10598015	10598094
ENSE00003745006	10603562	10603632
ENSE00003751023	10552657	10552716
ENSE00003751571	10543329	10543382
ENSE00003754579	10542395	10542448
ENSE00003909780	10521583	10521694

Expression profiles

Bgee: expression breadth broad, 26 present calls, max score 96.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.2707 / max 346.4333, expressed in 992 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
209264	2.6418	925
188480	0.5605	107
188479	0.0684	13

Top tissues by expression

102 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	96.29	gold quality
left testis	UBERON:0004533	95.14	gold quality
testis	UBERON:0000473	94.90	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.97	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.10	gold quality
placenta	UBERON:0001987	52.96	gold quality
colonic epithelium	UBERON:0000397	46.62	gold quality
sural nerve	UBERON:0015488	44.35	gold quality
cortex of kidney	UBERON:0001225	41.51	silver quality
calcaneal tendon	UBERON:0003701	40.88	gold quality
bone marrow cell	CL:0002092	40.87	gold quality
monocyte	CL:0000576	40.80	silver quality
cortical plate	UBERON:0005343	40.30	silver quality
ventricular zone	UBERON:0003053	40.14	gold quality
leukocyte	CL:0000738	40.10	silver quality
endometrium	UBERON:0001295	40.07	gold quality
right lobe of thyroid gland	UBERON:0001119	39.68	silver quality
smooth muscle tissue	UBERON:0001135	38.18	gold quality
skeletal muscle tissue	UBERON:0001134	38.05	gold quality
left lobe of thyroid gland	UBERON:0001120	37.97	gold quality
muscle tissue	UBERON:0002385	37.85	gold quality
bone marrow	UBERON:0002371	37.76	gold quality
thyroid gland	UBERON:0002046	37.65	silver quality
metanephros cortex	UBERON:0010533	37.45	silver quality
ganglionic eminence	UBERON:0004023	37.35	gold quality
corpus callosum	UBERON:0002336	36.25	gold quality
primary visual cortex	UBERON:0002436	35.94	gold quality
adrenal tissue	UBERON:0018303	35.78	gold quality
mucosa of transverse colon	UBERON:0004991	35.70	gold quality
body of stomach	UBERON:0001161	35.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

49 targeting TPTE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4425	100.00	67.59	1049
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-148A-5P	99.30	68.27	1141

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Gene dosage change of TPTE is associated with Robertsonian Down syndrome (PMID:18074101)
• TPTE sero-reactivity has moderate sensitivity. (PMID:26350112)
• Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker. (PMID:38546751)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tpte	ENSDARG00000056985
mus_musculus	Tpte	ENSMUSG00000031481
rattus_norvegicus	Tpte2	ENSRNOG00000024837

Paralogs (6): TNS1 (ENSG00000079308), HVCN1 (ENSG00000122986), TPTE2 (ENSG00000132958), TNS3 (ENSG00000136205), TMEM266 (ENSG00000169758), PTEN (ENSG00000171862)

Protein

Protein identifiers

Putative tyrosine-protein phosphatase TPTE — P56180 (reviewed: P56180)

Alternative names: Cancer/testis antigen 44, Transmembrane phosphatase with tensin homology, Tumor antigen BJ-HCC-5

All UniProt accessions (2): P56180, A0A087X1C4

UniProt curated annotations — full annotation on UniProt →

Function. Could be involved in signal transduction.

Subcellular location. Membrane.

Tissue specificity. Exclusively expressed in testis.

Isoforms (4)

UniProt ID	Names	Canonical?
P56180-1	1, Alpha	yes
P56180-2	2, Beta
P56180-3	3, Gamma
P56180-4	4, Delta

RefSeq proteins (5): NP_001277153, NP_001411945, NP_954868, NP_954869, NP_954870* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000387	Tyr_Pase_dom	Domain
IPR005821	Ion_trans_dom	Domain
IPR014020	Tensin_C2-dom	Domain
IPR016130	Tyr_Pase_AS	Active_site
IPR027359	Volt_channel_dom_sf	Homologous_superfamily
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR029023	Tensin_phosphatase	Domain
IPR035892	C2_domain_sf	Homologous_superfamily
IPR045102	PTP_VSP_TPTE	Domain
IPR051281	Dual-spec_lipid-protein_phosph	Family

Pfam: PF00520, PF10409, PF22785

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (18 total): sequence variant 6, transmembrane region 3, splice variant 3, domain 2, chain 1, region of interest 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P56180-F1	82.16	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 338

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1660514	Synthesis of PIPs at the Golgi membrane

MSigDB gene sets: 82 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, MODULE_205, BLALOCK_ALZHEIMERS_DISEASE_UP, GNF2_CCNA1, GOBP_DEPHOSPHORYLATION, GOBP_PROTEIN_DEPHOSPHORYLATION, WEBER_METHYLATED_HCP_IN_SPERM_UP, GOBP_TRANSMEMBRANE_TRANSPORT, WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN, chr21p11, CHEN_HOXA5_TARGETS_9HR_UP, KIM_WT1_TARGETS_DN, GOMF_PHOSPHATIDYLINOSITOL_PHOSPHATE_PHOSPHATASE_ACTIVITY, GOMF_PASSIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS

GO Biological Process (7): protein dephosphorylation (GO:0006470), signal transduction (GO:0007165), phosphate-containing compound metabolic process (GO:0006796), monoatomic ion transport (GO:0006811), dephosphorylation (GO:0016311), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085)

GO Molecular Function (7): protein tyrosine phosphatase activity (GO:0004725), monoatomic ion channel activity (GO:0005216), phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity (GO:0016314), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787), phosphatase activity (GO:0016791)

GO Cellular Component (2): cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
PI Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
transport	2
cellular anatomical structure	2
dephosphorylation	1
protein modification process	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
metabolic process	1
phosphate-containing compound metabolic process	1
monoatomic ion transport	1
transmembrane transport	1
phosphoprotein phosphatase activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
phosphatidylinositol trisphosphate phosphatase activity	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
phosphoric ester hydrolase activity	1
cytoplasm	1

Protein interactions and networks

STRING

1818 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TPTE	NEK3	P51956	785
TPTE	MAGEA3	P43357	745
TPTE	CTAG1A	P78358	732
TPTE	TYR	P14679	675
TPTE	MTMR2	Q13614	560
TPTE	PTEN	P60484	463
TPTE	HAUS6	Q7Z4H7	437
TPTE	TCHP	Q9BT92	423
TPTE	TMEM266	Q2M3C6	416
TPTE	NUDT21	O43809	406
TPTE	NDUFS6	O75380	405
TPTE	MTMR7	Q9Y216	401
TPTE	LUZP4	Q9P127	398
TPTE	SDHA	P31040	379
TPTE	NBPF4	Q96M43	378

IntAct

14 interactions, top by confidence:

A	B	Type	Score
TPTE	TLN1	psi-mi:“MI:0407”(direct interaction)	0.440
PIP5K1C	TPTE	psi-mi:“MI:0915”(physical association)	0.400
TPTE	ADRB2	psi-mi:“MI:0915”(physical association)	0.370
TPTE	ERBB3	psi-mi:“MI:0915”(physical association)	0.370
PDGFRB	TPTE	psi-mi:“MI:0915”(physical association)	0.370
TPTE	ROR2	psi-mi:“MI:0915”(physical association)	0.370
TPTE	NTRK1	psi-mi:“MI:0915”(physical association)	0.370
TPTE	PTK7	psi-mi:“MI:0915”(physical association)	0.370
TPTE	EPHA3	psi-mi:“MI:0915”(physical association)	0.370
TPTE	EPHA2	psi-mi:“MI:0915”(physical association)	0.370
TPTE	EPHA1	psi-mi:“MI:0915”(physical association)	0.370
TPTE	TUBB3	psi-mi:“MI:0915”(physical association)	0.370
P		psi-mi:“MI:0914”(association)	0.350

BioGRID (170): ATP2A2 (Affinity Capture-MS), EMD (Affinity Capture-MS), ENAH (Affinity Capture-MS), FANCD2 (Affinity Capture-MS), GCN1L1 (Affinity Capture-MS), SPAG9 (Affinity Capture-MS), TOR1AIP2 (Proximity Label-MS), SCYL3 (Proximity Label-MS), UBXN4 (Proximity Label-MS), TRMT10C (Proximity Label-MS), EMC3 (Proximity Label-MS), DDX54 (Proximity Label-MS), CLCC1 (Proximity Label-MS), VEZT (Proximity Label-MS), STAM2 (Proximity Label-MS)

ESM2 similar proteins: A1A4F0, A2QM49, A2ZIM4, E1BPQ3, E2R4X3, F4IXT6, N4WW42, O49567, O57428, O81514, P0C941, P18380, P38279, P50581, P52885, P56180, P68253, P86214, P86252, P86265, Q01741, Q0C8A7, Q0DWQ7, Q2QWX8, Q2RBJ4, Q2XXR3, Q3SZ89, Q4R6N0, Q5GH77, Q5HYJ1, Q5ZHX6, Q66H96, Q6UXP3, Q6YXZ1, Q7X7E9, Q7XT08, Q866X0, Q86UG4, Q86V35, Q8BFZ1

Diamond homologs: E9Q0S6, G5EE01, O08586, O54857, O94526, P56180, P60483, P60484, Q04205, Q4R6N0, Q54JL7, Q5SSZ5, Q63HR2, Q68CZ2, Q8CGB6, Q8H106, Q8T9S7, Q9FLZ5, Q9GLM4, Q9HBL0, Q9LT75, Q9P7H1, Q9PUT6, Q5B323, Q6XPS3, Q86IL4, Q99KY4, A0AUV4, A8WYE4, B0WAU8, D2I3C6, D3ZBE5, F1LP90, F1MH24, F1SPM8, G5ECQ3, O13773, O14976, O34507, O43066

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 13 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor protein tyrosine kinase signaling pathway	6	86.9×	7e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	4
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

3630 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
21:10605490:G:C	A532P	0.960
21:10603592:T:C	F494L	0.947
21:10603594:T:A	F494L	0.947
21:10603594:T:G	F494L	0.947
21:10605494:T:A	V533E	0.944
21:10592296:A:C	S365R	0.942
21:10592298:C:A	S365R	0.942
21:10592298:C:G	S365R	0.942
21:10605487:T:C	F531L	0.937
21:10605489:T:A	F531L	0.937
21:10605489:T:G	F531L	0.937
21:10569719:T:C	F235L	0.935
21:10569721:T:A	F235L	0.935
21:10569721:T:G	F235L	0.935
21:10595987:A:C	R392S	0.935
21:10595987:A:T	R392S	0.935
21:10605440:T:C	L515S	0.929
21:10602134:T:A	V478E	0.922
21:10605500:T:A	I535K	0.921
21:10602139:T:C	F480L	0.918
21:10602141:T:A	F480L	0.918
21:10602141:T:G	F480L	0.918
21:10592308:T:C	F369L	0.916
21:10592310:T:A	F369L	0.916
21:10592310:T:G	F369L	0.916
21:10605425:T:C	L510P	0.909
21:10605505:T:C	F537L	0.905
21:10605507:T:A	F537L	0.905
21:10605507:T:G	F537L	0.905
21:10578551:T:A	W325R	0.903

dbSNP variants (sampled 300 via entrez): RS1000019497 (21:10554389 A>G), RS1000022062 (21:10565025 G>A), RS1000074636 (21:10564709 T>A,C,G), RS1000231003 (21:10530947 G>A), RS1000297248 (21:10539835 C>A), RS1000322138 (21:10555978 A>G), RS1000425672 (21:10547635 G>T), RS1000566412 (21:10532862 G>A,C), RS1000662754 (21:10541787 G>A), RS1000732288 (21:10539352 T>A,C,G), RS1000761672 (21:10549655 A>G,T), RS1000960684 (21:10604048 C>G), RS1000991815 (21:10604540 C>A,T), RS1000994227 (21:10582554 G>A), RS1001033445 (21:10541989 G>T)

Disease associations

OMIM: gene MIM:604336 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002112_7	Celiac disease	2.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	decreases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Folic Acid	increases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder